Venaxis (Castle Rock, Colorado), an in vitro diagnostic company focused on obtaining FDA clearance for its APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, reported positive top-line results from its pivotal U.S. study.

Nearly 350,000 patients are treated for Kidney disease with an Endourlogical procedure. These patients typically experience less post-procedural pain and have faster recoveries than patients who are treated with more traditional approaches.